(Q37853356)

24 August 2017

0 references

1 reference

title

Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis (English)

1 reference

inflammatory bowel diseases

24 August 2017

main subject

0 references

0 references

0 references

1 reference

1

1 reference

24 August 2017

Paul Moayyedi

7

0 references

Charles N Bernstein

series ordinal

2

object named as

Charles N Bernstein

1 reference

24 August 2017

6

Nicholas J Talley

1 reference

24 August 2017

Khurram J Khan

3

1 reference

24 August 2017

Maria T Abreu

series ordinal

4

1 reference

24 August 2017

John K Marshall

series ordinal

5

1 reference

24 August 2017

language of work or name

English

0 references

publication date

15 March 2011

1 reference

The American Journal of Gastroenterology

24 August 2017

published in

1 reference

24 August 2017

volume

106

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

590-9; quiz 600

1 reference

Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Cortisone in ulcerative colitis; preliminary report on a therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Effects of glucocorticoids on gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

The effectiveness of budesonide therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Budesonide in inflammatory bowel disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Cortisone in ulcerative colitis; final report on a therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Oral fluticasone propionate in active distal ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.70

21 January 2018

Identifiers

DOI

10.1038/AJG.2011.70

1 reference

24 August 2017

1 reference